Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?

Rilan Bai; Naifei Chen; Tingting Liang; Lingyu Li; Zheng Lv; Xiaomin Lv; Jiuwei Cui

doi:10.3389/fonc.2020.00912

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?

Front Oncol. 2020 Jul 21:10:912. doi: 10.3389/fonc.2020.00912. eCollection 2020.

Authors

Rilan Bai¹, Naifei Chen¹, Tingting Liang¹, Lingyu Li¹, Zheng Lv¹, Xiaomin Lv², Jiuwei Cui¹

Affiliations

¹ Cancer Center, The First Hospital of Jilin University, Changchun, China.
² Department of Neurology, The First Hospital of Jilin University, Changchun, China.

Abstract

Considering the limited progress of chemotherapy and targeted therapy in improving the generally disappointing outcomes of advanced gastric or gastroesophageal junction cancer (GC/GEJC), immunotherapies have been gradually developed and advanced into novel frontiers of treatment for advanced GC/GEJC. Nevertheless, the response to immunotherapy was not always satisfactory, and the emergence of resistance was unavoidable. These factors prompt the development of different combination therapies and predictive and prognostic biomarkers of efficacy to improve the outcomes of patients with advanced GC/GEJC and to overcome drug resistance. This article discusses the advances of immune monotherapy, multiple current and ongoing clinical trials of immune combination therapy, immune-related adverse events, and various biomarkers in GC/GEJC.

Keywords: biomarkers; combination therapy; gastric or gastroesophageal junction cancer; immune related adverse events; immunotherapy.

Publication types

Review